Curis, Inc. announced that on September 19, 2022, Lori A. Kunkel, M.D. submitted her written resignation from the Board of Directors of the Company effective September 30, 2022. At the time of her resignation, Dr. Kunkel served as a member of the Board's Nominating and Corporate Governance Committee and as chair of the Board's Clinical Program Committee. The company believes that Dr. Kunkel resigned due to a fundamental difference in belief on company operations which, therefore, led her to the professional preference to no longer serve as a director, as discussed in the Resignation Letter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.52 USD | -10.85% | -32.82% | -17.49% |
05-14 | Transcript : Curis, Inc. - Special Call | |
05-14 | Curis, Inc. Announces Additional Data from Take Aim Leukemia Study | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.49% | 69.55M | |
+41.79% | 50.93B | |
-0.56% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+12.59% | 26.02B | |
-21.51% | 18.9B | |
+6.92% | 13.21B | |
+24.91% | 12.17B | |
+29.60% | 12.16B |
- Stock Market
- Equities
- CRIS Stock
- News Curis, Inc.
- Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022